Circulating Tumor Cell Diagnostics Market By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Circulating tumor cell (CTC) is a cell that shed into lymphatics from a primary tumor, carried around the body in the blood circulation. CTCs act as a liquid biopsy to diagnose and monitor cancer. CTC testing has been applied to over 500 clinical trials worldwide. As per studies Circulating tumor cell (CTC) assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.FDA has approved blood test for enumerating circulating tumor cells (CTCs). Circulating tumor cells (CTC) Test provides an early assessment of patient prognosis.

The Circulating Tumor Cell Diagnostics market was valued at 9.6 billion US$ in 2022 and is projected to reach 20.3 billion US$ by 2030, at a CAGR of 9.8% during the forecast period.

Market Dynamics

Rising Prevalence of Cancer is the key factor boosting the global Circulating Tumor Cell Diagnostics market. For instance, Cancer is the second leading cause of death globally. According to World Health Organization (WHO), an estimated 9.6 million deaths in 2018 due to cancer. According to the International Agency for Research on Cancer, the number of cancer cases per year is expected to rise 23.6 million by 2030.According to World Health Organization (WHO), in 2018, around 70% of deaths occur in low- and middle-income countries due to cancer. The most common cancers are Lung cancer with 2.09 million cases, followed by Breast cancer with 2.09 million cases, Colorectal cancer with 1.80 million cases, Prostate cancer with 1.28 million cases, Skin cancer with 1.04 million cases, and Stomach cancer with 1.03 million cases. Rising fund for circulating tumor cell research activities are key driving factors of the market. However, High cost of diagnostics might hamper the market growth. For instance, U.S. food and drug administration (FDA) has only approved CellSearch for detecting CTCs in 2014.The CellSearch system is expensive, 600,000∼800,000 USD, and the detection cost of each sample is high because antibodies are required to capture the CTCs in the blood. Development of cluster chip technology would provide lucrative opportunities for the market in the coming years.

Market Segmentation

Global Circulating Tumor Cell Diagnostics market is mainly classified based on Type, Application. Type is further segmented into CTC Enrichment, CTC Detection, CTC Analysis. CTC Enrichment is dominating the global Circulating Tumor Cell Diagnostics market due to the increasing clinical studies on CTC Enrichment. For instance, CellMax Life has introduced U.S. clinical study for circulating tumor cell (CTC) blood test for detecting colorectal cancer at the earliest, most treatable stages. By Application, the market is further divided into Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, Others.

Regional Analysis

Based on geography, the global Circulating Tumor Cell Diagnostics market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is dominating the global Circulating Tumor Cell Diagnostics market due to the increasing prevalence of cancer. For instance, According to American Cancer Society, in 2019, an estimate of1.76 million new cases of cancer, and 606,880 people will die from cancer in the U.S. In the United States Lung and bronchial cancer cause the highest number of cancer-related deaths. Around 66,020 women and 76,650 men died from Lung and bronchial cancer in 2019. According to the Canadian Cancer Society, in 2019, about 43,300 men, and 38,700 women died due to cancer in Canada. According to WHO, cancer was the cause of 12.84% of all deaths in Mexico in 2017. In 2017 the prevalence of cancer was 904,581.

North America Circulating Tumor Cell Diagnostics market size is expected to reach 6,956.8 million USD.

Competitive landscape

Key players operating in the Circulating Tumor Cell Diagnostics industry include Biocept, Epic Scicences, Inc., Fluxion Biosciences, Inc., Greiner Bio-one GmbH, Apocell Inc, Creatv Microtech, Inc., Ikonisys, Inc., Rarecell Diagnostics, Qiagen Adnagen, Screencell Silicon Biosystems, Advanced Cell Diagnostics (bio-techne).

The increasing investment by companies to develop circulating tumor cells (CTCs) diagnostics and clinical studies on circulating tumor cells (CTCs) are the key factors boosting the global Circulating Tumor Cell Diagnostics market. For instance,EMV Capital has invested in Vortex Biosciences. The new funding is to improve cancer detection and therapy by providing the best CTC sample workflow from a standard tube of blood.

Circulating Tumor Cell Diagnostics Market Segmentation

By Type
• CTC Enrichment
• CTC Detection
• CTC Analysis

By Application
• Tumorigenesis Research
• EMT Biomarkers Development
• Cancer Stem Cell Research
• Others
 
By Geography

• North America
o The U.S.
o Canada
o Mexico
• Europe
o U.K
o Germany
o France
o Italy
o Rest of Europe
• Asia Pacific
o India
o China
o Japan
o South Korea
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Rest of South America
• Middle East & Africa
o GCC Countries
o Egypt
o South Africa
o Rest of Middle East & Africa

Key Global Circulating Tumor Cell Diagnostics Industry Players

• Biocept
• Epic Scicences, Inc.
• Fluxion Biosciences, Inc.
• Greiner Bio-one GmbH
• Apocell Inc
• Creatv Microtech, Inc.
• Ikonisys, Inc.
• Rarecell Diagnostics
• Qiagen Adnagen
• Screencell Silicon Biosystems
• Advanced Cell Diagnostics (bio-techne)

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Circulating Tumor Cell Diagnostics Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence of Cancer
3.3.2. Rising fund for circulating tumor cell research activities
3.4. Restraints
3.4.1. High cost of diagnostics
3.5. Opportunity
3.5.1. Development of cluster chip technology
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. CTC Enrichment
4.2.1. Market Size & Forecast
4.3. CTC Detection
4.3.1. Market Size & Forecast
4.4. CTC Analysis
4.4.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Tumorigenesis Research
5.2.1. Market Size & Forecast
5.3. EMT Biomarkers Development
5.3.1. Market Size & Forecast
5.4. Cancer Stem Cell Research
5.4.1. Market Size & Forecast
5.5. Others
5.5.1. Market Size & Forecast

6. Circulating Tumor Cell Diagnostics Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Circulating Tumor Cell Diagnostics Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Circulating Tumor Cell Diagnostics Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Circulating Tumor Cell Diagnostics Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Circulating Tumor Cell Diagnostics Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Circulating Tumor Cell Diagnostics Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Biocept
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Biocept Product Category, Application, and Specification
7.1.3. Biocept Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Epic Scicences, Inc.
7.3. Fluxion Biosciences, Inc.
7.4. Greiner Bio-one GmbH
7.5. Apocell Inc
7.6. Creatv Microtech, Inc.
7.7. Ikonisys, Inc.
7.8. Rarecell Diagnostics
7.9. Qiagen Adnagen
7.10. Screencell Silicon Biosystems
7.11. Advanced Cell Diagnostics (bio-techne)